A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

Schizophrenia Research

Volumn 84, Issue 1, 2006, Pages 77-89

  Tandon, Rajiv ^a   Marcus, Ronald N ^b   Stock, Elyse G ^b   Riera, Linda C ^b   Kostic, Dusan ^b   Pans, Miranda ^b   McQuade, Robert D ^c   Nyilas, Margaretta ^c   Iwamoto, Taro ^d   Crandall, David T ^b  

^a Florida Department of Children and Families   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aripiprazole; Atypical antipsychotic; Clinical trial; Outpatient; RCT; Schizoaffective disorder; Schizophrenia; Switch study

Indexed keywords

ARIPIPRAZOLE;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; EVALUATION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; VOMITING;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PIPERAZINES; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; PSYCHIATRY; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33747481325     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.12.857     Document Type: Article

References (37)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
2. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
3. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., Ingenito G.G., and on behalf of the Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 166 (2003) 391-399
4. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
5. DeNayer A., Windhager E., Larmo I., Lindenbauer B., Rittmannsberger H., Platz T., Jones A.M., Whiteford J.L., Altman C.A., and on behalf of the SPECTRUM Study Group. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int. J. Psychiatry Clin. Pract. 7 (2003) 59-66
6. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
7. Goldman M., DeQuardo J.R., Tandon R., Taylor S.F., and Jibson M. Symptom correlates of global measures of severity in schizophrenia. Compr. Psychiatry 40 (1999) 458-461
8. Goodnick P.J., and Jerry J.M. Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother. 3 (2002) 1773-1781
9. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ. No. ADM 76-338) (1976), DHEW (Department of Health, Education, and Welfare) Publications, Rockville, MD 218-222
10. Hirose T., Uwahodo Y., Yamada S., et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol. 18 (2004) 375-383
11. Hudson T.J., Owen R.R., Thrush C.R., et al. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry 65 (2004) 211-216
12. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 441 (2002) 137-140
13. Kane J.M., Carson W.H., Saha A.R., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 (2002) 763-771
14. Kasper S., Lerman M.N., McQuade R.D., et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6 (2003) 325-337
15. Keith S.J., and Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. J. Clin. Psychiatry 64 (2003) 1308-1315
16. Kikuchi T., Tottori K., Uwahodo Y., et al. OPC-14597, a putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274 (1995) 329-336
17. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., Kessler F.H., Beyenburg S., and Naber D. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 38 (2005) 6-12
18. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., and Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63 (2002) 892-909
19. Lawler C.P., Prioleau C., Lewis M.M., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
20. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R.R. What does the PANSS mean?. Schizophr. Res. 79 (2005) 231-238
21. Lieberman J.A., Stroup S.T., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., and for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. N. Engl. J. Med. 353 (2005) 1209-1223
22. Mahmoud R., Engelhart L., Janagap C., et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorders. Clin. Drug Invest. 25 (2004) 275-286
23. Marder S.R., McQuade R.D., Stock E., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 (2003) 123-136
24. Moller H.-J. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J. Biol. Psychiatry 1 (2000) 75-91
25. Nasrallah H.A., Targum S.D., Tandon R., McCombs J.S., and Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 56 (2005) 273-282
26. Ohlsen R.I., O'Toole M.S., Purvis R.G., et al. Clinical effectiveness in first-episode patients. Eur. Neuropsychopharmacol. 14 (2004) S445-S451
27. Peuskens J. Clinical effectiveness in adults with chronic schizophrenia. Eur. Neuropsychopharmacol. 14 (2004) S453-S459
28. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., and Ingenito G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26 week study. J. Clin. Psychiatry 64 (2003) 1048-1056
29. Potkin S.G., Saha A.R., Kujawa M.J., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 (2003) 681-690
30. Seeman M.V. Clinical trials in psychiatry: do results apply to practice?. Can. J. Psychiatry 46 (2001) 352-355
31. Tandon R., and Fleischhacker W.W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr. Res. 79 (2005) 145-155
32. Tandon R., and Jibson M.D. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int. J. Psychiatry Clin. Pract. 9 (2005) 267-275
33. Tandon R., DeVellis R.F., Han J., Li H., Frangou S., Dursun S., and and the IAQ Validation Study Group. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 136 (2005) 211-221
34. Travis M.J., Burns T., Dursun T., Fahy T., Frangou S., Gray R., Haddad P.M., Hunter R., Taylor D.M., and Young A.H. Aripiprazole in schizophrenia: consensus guidelines. Int. J. Clin. Pract. 59 (2005) 485-495
35. Turner M., Eerdekens M., Karcher K., et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int. Clin. Psychopharmacol. 19 (2004) 241-249
36. Weiden P.J., Aquila R., Dalheim L., and Standard J.M. Switching antipsychotic medications. J. Clin. Psychiatry 58 Suppl. 10 (1997) 63-72
37. Weiden P.J., Simpson G.M., Potkin S.G., and O'Sullivan R.L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psychiatry 64 (2003) 580-588